Latest News
Organon & Co.
- Organon & Co. Estimates – FWB:7XP
- Organon plans third-quarter filing on October 19 for Organon stock
- Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026
- Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
- Organon stock sits 17.15 percent above USD 11.40 consensus target
- Organon reports six‑year MIUDELLA data as FDA reviews longer use
- Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
- Organon & Co stock hits 52-week high at 13.79 USD
- Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
- Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan
- Sun Pharma plans ₹10,000 crore bond sale to refinance Organon acquisition loan: Report
- Organon & Co. (OGN) Steadies Near $13.74 as Traders Watch the $14.43 Ceiling - Diamond Pattern
Headlines from the last 30 days, linking to the original publishers. See all market news →